See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $109B | 9.6x | 39.7x | |
| $10.5B | 3.5x | 14.3x | |
| $3.1B | 10.3x | 25.5x | |
| $3.0B | 8.9x | 24.0x | |
| $2.4B | 664.5x | -71.2x | |
| $2.1B | 8.0x | 33.4x | |
| $2.1B | 3.6x | 36.0x | |
| $1.5B | 38.0x | -3.3x | |
| $1.5B | 86.2x | -31.4x | |
| $1.5B | 411.8x | -64.5x | |
| $1.3B | n/a | n/a | |
| $863M | 2.4x | 11.1x | |
| $542M | 2.7x | 25.1x | |
| $527M | 8.9x | -1.2x | |
| $504M | 7.7x | 30.3x | |
| $449M | 15.9x | -2.7x | |
| $429M | 12.6x | 25.9x | |
| $404M | 0.8x | 8.0x | |
| $366M | n/a | n/a | |
| $366M | 114.5x | n/a | |
| $326M | 5.7x | -0.7x | |
| $309M | 5.0x | -13.8x | |
| $293M | 244.1x | n/a | |
| $192M | 0.6x | n/a | |
| $173M | 32.4x | -50.7x | |
| $159M | n/a | n/a | |
| $150M | 5.3x | 10.9x | |
| $132M | 1.1x | 14.5x | |
| $119M | n/a | n/a | |
| $106M | 12.7x | -4.6x | |
| $104M | 2.0x | 36.8x | |
| $95.0M | n/a | n/a | |
| $81.7M | 3.1x | -6.6x | |
| $80.9M | n/a | -5.8x | |
| $50.2M | 4601.3x | n/a | |
| $40.0M | n/a | n/a | |
| $28.5M | 6.1x | n/a | |
| $26.2M | n/a | n/a | |
| $24.8M | n/a | n/a | |
| $19.4M | 30.0x | n/a | |
| $8.0M | 2.3x | n/a | |
| $5.6M | 2.6x | n/a | |
| -$4.3M | n/a | n/a | |
| -$22.4M | -105.4x | 0.1x | |
| -$152M | -2.5x | 0.8x | |
| -$232M | -2802.0x | 1.3x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine